Phase II trial of dolastatin-10, a novel anti-tubulin agent, in metastatic soft tissue sarcomas

Sarcoma

Volumn 8, Issue 4, 2004, Pages 107-111

  Von Mehren, Margaret ^a   Balcerzak, S P ^b   Kraft, A S ^c   Edmonson, J H ^d   Okuno, S H ^d   Davey, M ^a   McLaughlin, S ^a   Beard, M T ^a   Rogatko, A ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

Anti microtubule agent; Dolastatin 10; Soft tissue sarcoma

Indexed keywords

ANTITUBULIN AGENT; DOLASTATIN 10; PENTAPEPTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SCREENING; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INJECTION SITE REACTION; LIVER TOXICITY; LYMPH NODE METASTASIS; MALE; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NIGHT SWEAT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY FAILURE; SACRUM; SIDE EFFECT; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; THORAX PAIN; TREATMENT OUTCOME; TUMOR VOLUME; VASCULAR DISEASE;

EID: 11244283696     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13577140400009163     Document Type: Article

References (32)

1. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1): 207-14.
2. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5(6): 840-50.
3. O'Bryan RM, Baker LH, Gottlieb JE, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977; 39(5): 1940-8.
4. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52(4): 626-32.
5. Elias A, Ryan L, Aisner J, Antman KH. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma. Semin Oncol 1990; 17(2 Suppl 4): 41-9.
6. Casper ES, Christman KL, Schwanz GK, Johnson B, Brennan MF, Bertino JR. Edatrexate in patients with soft tissue sarcoma. Activity in malignant fibrous histiocytoma. Cancer 1993; 72(3): 766-70.
7. Wagener DJ, Somers R, Santoro A, et al. Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1991; 27(12): 1604-5.
8. Roche H, Guiochet N, Kerbrat P, et al. Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma. Am J Clin Oncol 1993; 16(2): 137-9.
9. Zalupski MM, Benedetti J, Balcerzak SP, et al. Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study. Invest New Drugs 1993; 11(4): 337-41.
10. Licht JD, Gonin R, Antman KH. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 1991; 28(3): 223-5.
11. Bokemeyer C, Franzke A, Hartmann JT, et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997; 80(7): 1221-7.
12. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18(21): 3643-50.
13. Le Cesne A, Vassal G, Farace F, et al. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? J Immunother 1999; 22(3): 268-77.
14. Galanis E, Hersh E, Stopeck A, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17: 3313-23.
15. Gold JE, Masters TR, Bloom ND, et al. Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human soft-tissue sarcoma targets with potentiation by cis-diamminedichloroplatinum(II). J Surg Oncol 1995; 58(4): 212-21.
16. Casper ES, Cordon-Cardo C, Houghton AN, et al. Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma. Cancer Invest 1994; 12(1): 20-5.
17. Bai R, Pettit GR, Hamel E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 1990; 39(12): 1941-9.
18. Bai R, Roach MC, Jayaram SK, et al. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity. Biochem Pharmacol 1993; 45(7): 1503-15.
19. Hamel E. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992; 55(1): 31-51.
20. Bai R, Taylor GF, Cichacz ZA, et al. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry 1995; 34(30): 9714-21.
21. Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990; 66(5): 862-7.
22. Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 1995; 76(11): 2248-52.
23. van Hoesel QG, Verweij J, Catimel G, et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1994; 5(6): 539-42.
24. Petit G, Kamano Y, Herald C, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc 1987; 109: 6883-5.
25. Kalemkerian GP, Ou X, Adil MR, et al. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 1999; 43(6): 507-15.
26. Hoffman M, Blessing J, Lentz S. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 89: 95-8.
27. Cheson B, Zwiebel J, Dancey J, Murgo A. Novel Therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol 2000; 27(5): 560-77.
28. Pitot H, McElroy E, Reid J, et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999; 5: 525-31.
29. van Glabbeke M, Verweij J, Judson I, Nielsen OS. EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002; 38: 543-9.
30. Plaat BEC, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18(18): 3211-20.
31. Toppmeyer DL, Slapak CA, Croop J, Kufe DW. Role of P-glycoprotein in dolastatin 10 resistance. Biochem Pharmacol 1994; 48(3): 609-12.
32. Blay J, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-9.